Comparative Study of PD-L1 Expression in Different Sites of Non-small Cell Lung Cancer
Background and objective The expression of programmed cell death ligand 1 (PD-L1) as a biomarker for immunotherapy in non-small cell lung cancer (NSCLC) is routinely detected in clinical pathology department. However, the spatial heterogeneity of PD-L1 expression in intrapulmonary tumors and extrapu...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-05-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.14 |
| _version_ | 1828322011475083264 |
|---|---|
| author | Xiaozheng HUANG Jianghua WU Lixin ZHOU Zhijie SONG Wantong XU Ling JIA Xinting DIAO Qi WU Dongmei LIN |
| author_facet | Xiaozheng HUANG Jianghua WU Lixin ZHOU Zhijie SONG Wantong XU Ling JIA Xinting DIAO Qi WU Dongmei LIN |
| author_sort | Xiaozheng HUANG |
| collection | DOAJ |
| description | Background and objective The expression of programmed cell death ligand 1 (PD-L1) as a biomarker for immunotherapy in non-small cell lung cancer (NSCLC) is routinely detected in clinical pathology department. However, the spatial heterogeneity of PD-L1 expression in intrapulmonary tumors and extrapulmonary metastases is still a challenge for the clinical testing. This study aims to explore the differences of PD-L1 expression in test samples obtaining from different sites of NSCLC. This study may contribute to the detection strategy of PD-L1 in patients with advanced lung cancer. Methods One hundred and thirty-one cases of consecutively detected PD-L1 (22c3 assay, Dako) staining in metastatic NSCLC and 972 cases of non-paired intrapulmonary NSCLC were collected. The discrepancies of tumor proportion score (TPS) of PD-L1 expression in intrapulmonary samples and extrapulmonary metastatic samples of different sites were compared. Results The positive expression rate of PD-L1 in extrapulmonary metastatic NSCLC (TPS ≥ 1%) was 61.83%, and the TPS was significantly higher than that in intrapulmonary tumors (P=0.03). The PD-L1 scores of the specimens obtained from different sites were significantly different (P=0.007). The positive rates of PD-L1 in liver and adrenal metastases were 85.71% and 77.78% respectively, and their TPS were significantly higher than that of the intrapulmonary samples (P<0.05). The positive rates of PD-L1 in lymph node, bone, brain, soft tissue, and pleural metastases was 40.00%-66.67%, with no significant differences compared to intrapulmonary tumors. The analysis of histological subtype and sample type showed that the PD-L1 score of extrapulmonary samples of adenocarcinoma subtype or surgical specimen was significantly higher than that of intrapulmonary tumors. The analysis of clinicopathological parameters showed that the PD-L1 positive expression or high expression were significantly correlated with male patients, smoking history, and epidermal growth factor receptor (EGFR) wild type. Conclusion The expression of PD-L1 in metastatic NSCLC is generally higher than that in intrapulmonary tumor, and the positive rate of PD-L1 expression was discrepant in different sites of specimen. The differences of PD-L1 score between extrapulmonary metastatic samples and intrapulmonary samples may be associated with different metastatic sites, histological subtype, and specimen type. |
| first_indexed | 2024-04-13T18:34:42Z |
| format | Article |
| id | doaj.art-ed308cd7eee44d5b9ed129967f85fd36 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-04-13T18:34:42Z |
| publishDate | 2022-05-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-ed308cd7eee44d5b9ed129967f85fd362022-12-22T02:34:56ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872022-05-0125530331010.3779/j.issn.1009-3419.2022.102.14Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung CancerXiaozheng HUANG0Jianghua WU1Lixin ZHOU2Zhijie SONG3Wantong XU4Ling JIA5Xinting DIAO6Qi WU7Dongmei LIN8Department of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin’s Clinical Research Center of Cancer, Tianjin 300060, ChinaDepartment of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaDepartment of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaDepartment of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaDepartment of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaDepartment of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaDepartment of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaDepartment of Pathology, Peking University Cancer Hospital & Institute; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, ChinaBackground and objective The expression of programmed cell death ligand 1 (PD-L1) as a biomarker for immunotherapy in non-small cell lung cancer (NSCLC) is routinely detected in clinical pathology department. However, the spatial heterogeneity of PD-L1 expression in intrapulmonary tumors and extrapulmonary metastases is still a challenge for the clinical testing. This study aims to explore the differences of PD-L1 expression in test samples obtaining from different sites of NSCLC. This study may contribute to the detection strategy of PD-L1 in patients with advanced lung cancer. Methods One hundred and thirty-one cases of consecutively detected PD-L1 (22c3 assay, Dako) staining in metastatic NSCLC and 972 cases of non-paired intrapulmonary NSCLC were collected. The discrepancies of tumor proportion score (TPS) of PD-L1 expression in intrapulmonary samples and extrapulmonary metastatic samples of different sites were compared. Results The positive expression rate of PD-L1 in extrapulmonary metastatic NSCLC (TPS ≥ 1%) was 61.83%, and the TPS was significantly higher than that in intrapulmonary tumors (P=0.03). The PD-L1 scores of the specimens obtained from different sites were significantly different (P=0.007). The positive rates of PD-L1 in liver and adrenal metastases were 85.71% and 77.78% respectively, and their TPS were significantly higher than that of the intrapulmonary samples (P<0.05). The positive rates of PD-L1 in lymph node, bone, brain, soft tissue, and pleural metastases was 40.00%-66.67%, with no significant differences compared to intrapulmonary tumors. The analysis of histological subtype and sample type showed that the PD-L1 score of extrapulmonary samples of adenocarcinoma subtype or surgical specimen was significantly higher than that of intrapulmonary tumors. The analysis of clinicopathological parameters showed that the PD-L1 positive expression or high expression were significantly correlated with male patients, smoking history, and epidermal growth factor receptor (EGFR) wild type. Conclusion The expression of PD-L1 in metastatic NSCLC is generally higher than that in intrapulmonary tumor, and the positive rate of PD-L1 expression was discrepant in different sites of specimen. The differences of PD-L1 score between extrapulmonary metastatic samples and intrapulmonary samples may be associated with different metastatic sites, histological subtype, and specimen type.http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.14lung neoplasmsprogrammed cell death ligand 1heterogeneitytumor proportion score |
| spellingShingle | Xiaozheng HUANG Jianghua WU Lixin ZHOU Zhijie SONG Wantong XU Ling JIA Xinting DIAO Qi WU Dongmei LIN Comparative Study of PD-L1 Expression in Different Sites of Non-small Cell Lung Cancer Chinese Journal of Lung Cancer lung neoplasms programmed cell death ligand 1 heterogeneity tumor proportion score |
| title | Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer |
| title_full | Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer |
| title_fullStr | Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer |
| title_full_unstemmed | Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer |
| title_short | Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer |
| title_sort | comparative study of pd l1 expression in different sites of
non small cell lung cancer |
| topic | lung neoplasms programmed cell death ligand 1 heterogeneity tumor proportion score |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.14 |
| work_keys_str_mv | AT xiaozhenghuang comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT jianghuawu comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT lixinzhou comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT zhijiesong comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT wantongxu comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT lingjia comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT xintingdiao comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT qiwu comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer AT dongmeilin comparativestudyofpdl1expressionindifferentsitesofnonsmallcelllungcancer |